Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06185335 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A

Name: A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A — clinical trial record (NCT06185335)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EDELWEISS

StatusActive, Not Recruiting

PhasePhase 1/2

SponsorBiocad

Started2023-07-26

View on ClinicalTrials.gov ↗

Record status

This record was last updated April 24, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Amendment history

2025-04-22

Recruiting→Active, Not Recruiting Study Status, Oversight, Arms and Interventions, Contacts/Locations v1

Trial statusRecruiting→Active, Not Recruiting

Study sitesdetails revised at 17 of 17 sites

2023-12-14

Original filing

Biocad

26 trials monitored

See all monitored trials

Hemophilia

231 trials monitored

See 10 trials at risk

The goal of this multicenter, two-stage, open-label study is to investigate the safety, immunogenicity, and efficacy of ANB-010 in subjects with hemophilia A. The study will have a dose-escalation design with elements of phase I/II seamless adaptive design.

Trial Details

NCT Number	NCT06185335
Lead Sponsor	Biocad
Conditions	Hemophilia A
Enrollment	50 participants
Start Date	2023-07-26
Primary Completion	2025-12 (estimated)
Study Completion	2033-06 (estimated)
Updated on ClinicalTrials.gov	2025-04-24